Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

Author： Romano A.   Chiarenza A.   Consoli U.   Conticello C.   Forte S.   Uccello G.   Vetro C.   Cavalli M.   Coppolino F.   Palumbo G. A.   Di Raimondo F.  

Publisher： Oxford University Press

ISSN： 0923-7534

Source： Annals of Oncology, Vol.24, Iss.4, 2013-04, pp. : 1038-1044

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

By Srkalovic Gordan   Elson Paul   Trebisky Beth   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 219-226

Humana Press, Inc

Access to resources Recommend Favorite

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

By Held Lauren A.   Rizzieri David   Long Gwynn D.   Gockerman Jon P.   Diehl Louis F.   Castro Carlos M. de   Moore Joseph O.   Horwitz Mitchell E.   Chao Nelson J.   Gasparetto Cristina  

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 172-176

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

By Wong Doo Nicole  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

Activity and toxicity profiles of the combinations bendamustine–lenalidomide–dexamethasone and bendamustine–bortezomib–dexamethasone for advanced stage multiple myeloma

By Mele Giuseppe   Spina Alessandro   Guaragna Gianluca   Giannotta Angela   Melpignano Angela   Quarta Gianni  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1191-1193

Informa Healthcare

Access to resources Recommend Favorite

Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

By Chim C.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 181-182

Springer Publishing Company

Access to resources Recommend Favorite